Pure Global
NCT06420388

2% Lidocaine Gel in Reducing Postoperative Pain Following Haemorrhoidectomy

Efficacy of 2% Lidocaine Gel in Reducing Postoperative Pain and Analgesic Consumption Following Haemorrhoidectomy: A Randomized, Double-Blind, Controlled Trial
E-DA Hospital·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Surgery,Pain, Postoperative
Drug/Device/Intervention
2% Lidocaine Gel
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
E-DA Hospital
Location
Kaohsiung, Taiwan
Timeline & enrollment
Phase
N/A
Start date
May 01, 2023
End date
Oct 01, 2024
Enrollment
400 participants
Primary outcome

Postoperative pain

Summary

The study is a randomized, double-blind, controlled trial evaluating the efficacy of 2%
 lidocaine gel in reducing postoperative pain and analgesic consumption after
 haemorrhoidectomy. 222 patients undergoing Ferguson haemorrhoidectomy will be randomly
 assigned to receive either 2% lidocaine gel or a non-anaesthetic lubricant gel control. Pain
 scores using a visual analog scale (VAS) will be assessed at 12 and 24 hours, and 2, 3, and 7
 days postoperatively. Analgesic consumption will also be measured.

ICD-10 classifications
During surgical operationDuring surgical operationDuring surgical operationOther surgical proceduresDuring other surgical and medical care
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06420388
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06420388 through Pure Global AI's free database. This phase not specified trial is sponsored by E-DA Hospital and is currently Recruiting. The study focuses on Surgery,Pain, Postoperative. Target enrollment is 400 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.